FindTrial
Sign In

Individualized treatment and clinical validation of osteosarcoma based on MiniPDX susceptibility test

Individualized treatment and clinical validation of osteosarcoma based on MiniPDX susceptibility test

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026540
Enrollment
Unknown
Registered
2019-10-13
Start date
2019-10-14
Completion date
Unknown
Last updated
2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteosarcoma

Interventions

Case series:Establishment of PDX model and MiniPDX susceptibility test using tumor specimens

Sponsors

First Affiliated Hospital of the Fourth Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Pathological histological diagnosis of osteosarcoma patients aged 8-40 years old; 2. The patients could provide biopsy,fresh tumor samples; 3. Objective tumors that meet RECIST 1.1 criteria and can be evaluated by CT/MRI; 4. KPS score >=60, expected survival time >=3 months; 5. The patient voluntarily signed the informed consent form, with good compliance.

Exclusion criteria

Exclusion criteria: 1. Patients with incomplete clinical data; 2. Those who have not undergone surgery or have unplanned reoperation after surgery; 3. The patient was found to have a second tumor during the treatment and interfered with the study.

Design outcomes

Primary

MeasureTime frame
ORR;—

Secondary

MeasureTime frame
PFS;OS;Life quality;Limb salvage rate;—

Countries

China

Contacts

Public ContactZhen Wang

First Affiliated Hospital of the Fourth Military Medical University

longyao210@qq.com+86 029-84775281

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026